Evonik's Strategic Pivot: Dividend Adjustment Amidst Upgraded Outlook

Specialty chemicals group Evonik finds itself at a crossroads, balancing a positive analyst reassessment against internal cost pressures and a revised shareholder returns policy. The latest analysis from British investment bank Barclays points to emerging strengths, even as the company prepares for challenging wage talks and a lower dividend payout.

Barclays Revises Rating on Supply Chain Shift

In a significant move, Barclays analyst Anil Shenoy has upgraded Evonik's stock from "Equal Weight" to "Overweight." Concurrently, the bank raised its price target from €16 to €17 per share. This revised outlook is primarily driven by unexpected developments in the global supply chain for methionine, a key animal feed additive.

Geopolitical tensions in the Middle East are placing pressure on Asian producers, forcing global buyers to seek alternative sources. As the largest producer outside of Asia, Evonik stands to gain substantially from this realignment. The company's management acted swiftly, implementing a global 10% price increase for its MetAMINO product in early March. Consequently, Barclays has adjusted its full-year EBITDA estimate upward to €1.89 billion and revised its net price effect assumption from minus €105 million to zero.

Internal Cost Discipline Faces External Pressure

Despite this operational tailwind, significant cost risks loom on the domestic front. The third round of collective bargaining for the German chemical industry threatens a settlement that could undermine Evonik's ambitious savings program. The company aims to achieve annual savings of approximately €400 million by the end of 2026, with around 80% of that figure—€320 million—expected to come from the global reduction of 2,000 positions.

Should investors sell immediately? Or is it worth buying Evonik?

Trade unions are pushing for substantial wage increases, while employers cite persistently high energy costs and a fragile economic climate. A costly compromise in the negotiations would directly impact management's calculations and put pressure on margins.

Shareholder Returns Framework Gets an Overhaul

Investors are also navigating a change in the company's capital allocation strategy. To bolster financial flexibility, Evonik is adopting a new dividend policy. Henceforth, the company intends to distribute between 40% and 60% of its adjusted net income to shareholders.

For the concluded 2025 fiscal year, the management board will propose a transitional dividend of €1.00 per share at the Annual General Meeting on June 3. This represents a reduction from the previous year's payout of €1.17 per share. Even with this cut, the dividend yields approximately 7% at the current share price. Furthermore, the company aims to fill the vacant CFO position, which has been open since September 2025, before the shareholder gathering in Essen.

Evonik at a turning point? This analysis reveals what investors need to know now.

Forthcoming Quarterly Report to Provide Validation

The market will gain clearer insight into the methionine price impact when Evonik releases its first-quarter results on May 8. These figures will show the extent to which the price increases are already bolstering operational performance.

After reporting an adjusted EBITDA of €1.87 billion for the past year, the company's guidance for 2026 sits in a range of €1.7 billion to €2.0 billion. Achieving the upper end of this target will largely depend on whether the company can maintain its cost discipline in the face of the impending wage agreement.

Ad

Evonik Stock: New Analysis - 30 March

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...

DE000EVNK013 | EVONIKS | boerse | 69027521 |